KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat.

DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic ...

KRAS mutations are among the most common genetic alterations in cancer and are considered particularly difficult to treat. In ...

Ahead of World No Tobacco Day, Dr Gregory J. Riely, in an interview with Express Healthcare, highlights how tobacco fuels ...

Annual Meeting is scheduled to take place in Chicago, Illinois, USA from May 30 to June 3. Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (6990.HK, the "Company") will present results from six ...

New data from several studies of compounds discovered by HUTCHMED (00013.HK) including savolitinib, ranosidenib, fruquintinib ...

Data will be shared in two oral presentations, a poster and two online abstractsHighlights include a potential novel, ...

HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:?HCM; HKEX:?13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

Dr. Samuel Rosner, a thoracic oncologist at the University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, said a growing number of people, particularly women under 65, are ...